[{"from": "human", "value": "Could you provide a description of this molecule? [C][C][Branch1][C][C][C][C@@H1][C][N][C][C][C][=C][C][=Branch2][Ring1][S][=C][Branch2][Ring1][#Branch2][C][=C][Ring1][=Branch1][C@H1][Ring1][#Branch2][C][C@H1][Ring1][=C][O][C][=Branch1][C][=O][C@H1][Branch1][=Branch1][C][Branch1][C][C][C][N][O][C][O][C]"}, {"from": "gpt", "value": "The molecule has been used in trials studying the treatment and basic science of Tourette Syndrome and Tardive Dyskinesia. In April, 2017, valbenazine was approved by the FDA (as Ingrezza) as the first and only approved treatment for adults with Tardive Dyskinesia (TD)."}]